Quick Facts

• Therapeutic Domain: Used to support immunity against the rabies virus.
• Primary Use: Management of post-exposure prophylaxis following potential exposure to the rabies virus.
• Secondary Use: May be used in pre-exposure settings for individuals at elevated risk of exposure.

---

Speeda is an approved vaccine formulation designated for use in human populations. Its primary therapeutic role is to provide immunity against the rabies virus. This is achieved through the support of the body’s natural ability to produce protective antibodies.

Main Uses and Benefits

Speeda is commonly administered for post-exposure prophylaxis (PEP). This means it is used following potential exposure to the rabies virus—typically after a bite or scratch from an animal suspected of carrying the disease—to help mitigate the risk of developing rabies. Its use in this context is essential to support a critical public health response.

In addition to PEP, the medication may be utilized for pre-exposure prophylaxis (PrEP) in individuals whose occupation or travel plans place them at a higher, sustained risk of rabies exposure. This prophylactic use helps prepare the body’s immune system ahead of time. The benefits of using this medication include contributing to the prevention of disease onset in exposed individuals, aligning with global standards for managing this condition. Patients should consult their healthcare provider to determine the appropriate regimen based on their specific needs and exposure status.

Regulatory References

1. WHO Medical Product Alert N°8/2019 Falsified Rabies Vaccines and Anti-Rabies Serum circulating in the Philippines

The official regulatory profile for Speeda (Purified Rabies Vaccine, Inactivated) is primarily defined by the context of use: life-saving treatment versus elective prevention.

Populations for Whom Use is Contraindicated

For Post-Exposure Prophylaxis (PEP), which is a life-saving measure, regulatory guidance confirms there are no absolute contraindications due to the nearly 100% fatality rate of rabies. A formal contraindication is reserved only for the Pre-Exposure Prophylaxis (PrEP) setting: individuals with a known life-threatening systemic hypersensitivity reaction to any vaccine component must not receive the elective regimen (FDA).

Eligibility and Conditional Use

Age-Group Eligibility: The vaccine is formally approved for use in all age groups, including infants, children, adolescents, and adults. Appropriate studies have not demonstrated pediatric-specific issues that would limit its general use.

Physiological Status: Pregnancy and lactation are not defined as contraindications for receiving the vaccine in the emergency PEP setting (CDC).

Conditional Eligibility: Patients with altered immunocompetence, including those on immunosuppressive therapy, are eligible but may have a reduced immune response (FDA). This conditional status may require a specific regimen and post-vaccination testing to ensure protection. Furthermore, use in the elective PrEP setting may be temporarily postponed for those with severe acute febrile illness (NIH).

The official regulatory profile for Speeda, an inactivated rabies vaccine, focuses primarily on pharmacodynamic interactions that may impair the development of active immunity against the rabies virus.

Interactions with Immune-Modifying Agents

Co-administration with immunosuppressive treatments, including long-term systemic corticosteroids, chemotherapy (e.g., alkylating agents, antimetabolites), and other immunosuppressive agents, is officially documented to potentially interfere with the production of protective antibodies. This interaction may result in an inadequate or suppressed immune response to the vaccine series. Regulatory guidance notes that these agents should generally be avoided during post-exposure therapy unless their use is essential for managing other critical conditions.

Procedural and Substance Constraints

When used as part of the post-exposure regimen, the co-administration of Rabies Immunoglobulin (RIG) is subject to a mandatory administration constraint. Official documents strictly mandate that the vaccine and RIG must never be mixed in the same syringe or injected into the same anatomical site to prevent the local interference of the vaccine’s effect. Additionally, the use of antimalarial drugs such as chloroquine is officially noted to potentially reduce the immune response to the vaccine. Furthermore, regulatory labels caution that immunocompromised individuals may have a reduced capacity to achieve the full desired immune response, a documented population-specific interaction note.

Speeda is a Purified Vero Cell Rabies Vaccine (PVRV), classified as an inactivated vaccine. Its biological target is the host immune system, specifically antigen-presenting cells (APCs) such as dendritic cells, located in the muscle tissue following intramuscular administration.

The vaccine contains inactivated rabies virus antigen, derived from the Pasteur vaccine strain. Upon introduction, the viral antigen is processed by APCs. The APCs then present these processed antigens via Major Histocompatibility Complex (MHC) molecules to T-helper cells ( CD4+), initiating the adaptive immune cascade. This interaction triggers the activation and proliferation of antigen-specific T-helper cells.

The activated T-helper cells subsequently provide necessary co-stimulatory signals to B lymphocytes (B cells) that have recognized the antigen. This downstream cascade results in the proliferation and differentiation of B cells into plasma cells and memory B cells.

The plasma cells function as cellular factories, secreting high titers of neutralizing antibodies ( IgG) specific to the rabies virus glycoprotein. The system-level physiological consequence of this process is the establishment of a humoral immune response where circulating antibodies can bind to and prevent the entry and replication of the rabies virus in host cells.

Administration Guidelines for Speeda (Purified Rabies Vaccine)

Speeda is a purified rabies vaccine that must be administered by a healthcare professional following strict regulatory guidelines. It is supplied as a freeze-dried powder in a vial, which must be reconstituted immediately before use with the provided solvent, Water for Injection, to achieve the official 2.5 IU (International Units) strength per dose.

Official Administration Protocol

Guideline Element	Official Instruction
Route of Administration	Intramuscular (I.M.) or Intradermal (I.D.)
Standard Dosing	The schedule consists of a multi-dose series (e.g., 5-dose Essen regimen) administered on specified days (e.g., Day 0, 3, 7, 14, 28) for post-exposure prophylaxis or a shorter series for pre-exposure prophylaxis.
Injection Site	For adults and older children, the I.M. injection is administered into the deltoid muscle; for young children, the anterolateral thigh is the preferred site. Administration into the gluteal region is prohibited as it may reduce efficacy.
Preparation	The powder must be dissolved completely with the 0.5 mL solvent, creating a clear, homogeneous solution that is administered immediately after reconstitution.

Procedural Summary

All doses must adhere to the specific dosing schedule and interval outlined in the full product insert. The administration route and anatomical site are procedural requirements designed to ensure proper use according to government regulatory standards. No dose adjustment is typically required for children; they receive the same standardized dose volume as adults. For all exposure cases, the first dose marks Day 0 of the administration series.

Overview of Clinical Studies for Speeda

Evidence for Post-Exposure Prophylaxis (PEP)

Research for using the purified Vero cell rabies vaccine after a potential rabies exposure primarily involves Randomized Controlled Trials (RCTs). These studies examine immunogenicity, or how the body responds to the vaccine, by monitoring the percentage of participants who reach a pre-defined Rabies Virus Neutralizing Antibody (RVNA) titer (ge 0.5 IU/mL). This antibody level is considered a surrogate endpoint because it is used as a stand-in for observing the actual prevention of rabies disease, which is rare. Studies generally report patterns of high rates of reaching the target antibody titer when the vaccine was evaluated using approved schedules. The findings describe group patterns observed in research, but direct, long-term clinical efficacy against the disease remains limited to this surrogate measure.

Evidence for Pre-Exposure Prophylaxis (PrEP)

The vaccine has also been examined for preventive purposes (PrEP) in individuals at ongoing risk. The goal of these studies was to measure the seroconversion rate following the primary vaccination course. Researchers monitored the anamnestic response, which describes the measurement of a rapid antibody response following a subsequent booster dose. As with PEP studies, the research relies on antibody levels as a surrogate outcome. While initial seroconversion appears to be consistently reported, certainty remains low regarding the very long-term persistence of antibodies across all schedules studied.

Research Gaps and Limitations

The research base has two key limitations. First, the reliance on immunogenicity as a surrogate means direct evidence proving prevention of clinical rabies disease is limited. The presence of antibodies is used as a marker for protection in studies, but this does not predict individual outcomes. Second, while follow-up has extended to several years in some cohorts, long-term effects are not fully established across all currently used schedules. Research in certain severely immunocompromised groups may also be less extensive or subject to ongoing study.

Common questions about Speeda (FAQ)

Q: Can you take Speeda with basic pain relievers like Tylenol?

Official documents for the vaccine focus on interactions with specific substances known to suppress the immune system, such as immunosuppressive drugs or certain antimalarial medications. There are typically no general warnings noted in the regulatory labeling regarding common, non-prescription pain relievers.

Q: Does Speeda interact with common supplements like multivitamins or fish oil?

Regulatory information primarily addresses interactions with medications that are known to interfere with the immune response. Interactions with common dietary supplements like multivitamins or fish oil are generally not specified in the official vaccine labeling.

Q: What are the contraindications listed for Speeda?

For Post-Exposure Prophylaxis (PEP), official guidance states there are no absolute contraindications. For Pre-Exposure Prophylaxis (PrEP), a life-threatening systemic hypersensitivity reaction to any component is a contraindication. Additionally, official guidance indicates that Pre-Exposure Prophylaxis (PrEP) may be temporarily postponed for individuals with a severe acute febrile illness.

Q: Does Speeda need to be taken at a specific time of day?

The official schedules for administering the vaccine specify the days on which the doses must be given to ensure proper timing (e.g., Day 0, 3, 7). However, regulatory guidelines do not specify a particular time of day for the injection.

Q: Can I take Speeda with my blood pressure medicine?

Regulatory documents prioritize warnings about drugs that interfere with the immune response to the vaccine. General warnings for interactions with common, non-immunosuppressive medications like most blood pressure medicines are typically not specified in the official labeling.

Q: Does Speeda interact with alcohol?

Official regulatory labels focus on medication interactions that may reduce the immune response to the vaccine. They typically do not contain mandatory warnings prohibiting the consumption of alcohol.

Q: Does Speeda interact with birth control pills?

Regulatory labeling lists interactions primarily with immunosuppressive agents that could reduce the body’s ability to respond to the vaccine. There are no documented warnings in official sources regarding an interaction between this type of inactivated vaccine and hormonal birth control pills.

Q: Does Speeda interact with common psychiatric medications?

Regulatory warnings focus on medications known to suppress the immune system. Unless a psychiatric medication has known immunosuppressive properties, it is generally not listed as an interacting substance in the official vaccine documents.

Q: Does Speeda affect your mood or energy levels?

The safety profile lists malaise (a general feeling of being unwell) and headache as Very Common or Common adverse reactions. These non-specific systemic effects may temporarily relate to a change in perceived mood or energy.

Q: What happens if you miss a day of taking Speeda?

Official guidelines state that regulatory guidance advises against restarting the vaccination series due to minor delays in the schedule. If a dose is missed, the missed dose is administered immediately upon presentation, and the remaining doses should be adjusted to maintain the recommended intervals.

Q: Can older adults safely be prescribed Speeda?

According to official product information, the vaccine is approved for use in all age groups, including infants, children, adolescents, and adults. No specific safety issues are typically noted for older adults that would limit its use.

Q: Does Speeda require lab tests or monitoring while taking it?

Routine laboratory testing is generally not required for healthy individuals. However, for patients with altered immunocompetence (e.g., those on immunosuppressive therapy), official guidelines indicate that post-vaccination serologic testing to confirm an adequate antibody response is generally required.

Q: Can Speeda be taken while pregnant or breastfeeding?

Due to the high fatality rate of rabies, pregnancy and lactation are not contraindications for receiving the vaccine when used for life-saving Post-Exposure Prophylaxis (PEP). Official guidance prioritizes the need for protective immunity in this emergency setting.

Q: If I feel better, can I stop taking Speeda on my own?

Official regulatory guidance describes the need for the post-exposure prophylaxis (PEP) regimen to be completed as prescribed. The documented benefit of the vaccine is based on the administration of all recommended doses, regardless of whether a person feels well or not during the series.

Q: Does Speeda have any warnings about driving or operating machinery?

Common adverse reactions listed in the safety profile include headache and dizziness. Official labels indicate that patients who experience these symptoms may be advised to exercise caution when driving or operating machinery until the symptoms subside.

Q: Are there different forms of Speeda (tablet, liquid, extended-release)?

Speeda is supplied only as a freeze-dried powder in a vial, which must be reconstituted into a suspension for injection. No other forms, such as tablets or extended-release capsules, are mentioned in the official labeling.

Q: What is the difference between the standard and extended-release versions of Speeda?

Speeda is only available as a single formulation: a freeze-dried powder for injection. Official regulatory documentation does not list or describe a separate extended-release version of the product.

Q: What should I do if I accidentally take too much Speeda?

Official prescribing information notes that in the case of a suspected overdose, regulatory information recommends contacting a healthcare professional immediately. Official documents advise seeking emergency medical help for a suspected overdose.

Q: Is it normal to feel a difference right away when starting Speeda?

Speeda works by stimulating the immune system to create protective neutralizing antibodies over time. The development of a full protective response is a gradual process and is not expected to result in an immediate physical sensation or feeling of difference right away.

Q: Is it true that Speeda is a derivative of another common drug?

Official composition documents state that the vaccine contains inactivated Rabies Virus Antigen derived from the Pasteur strain, which is cultivated on Vero cells. It is classified as a biological product, not a chemical derivative of another common drug.

The storage and disposal of Speeda (Purified Rabies Vaccine) must adhere strictly to the conditions specified in official regulatory labeling.

Storage Conditions

The unreconstituted vaccine powder must be maintained within the mandated refrigerated temperature range of 2 C to 8 C and must not be frozen. Freezing irreversibly damages the vaccine's potency. To ensure stability, the vial should be stored in its original package to protect from light and kept out of the sight and reach of children.

Stability and Disposal

The vaccine has a shelf life of 36 months when stored correctly. Once the lyophilized powder is mixed with the diluent, the resulting suspension must be used immediately.

Disposal of any unused product or waste materials, including the emptied vials, must be carried out according to local requirements for pharmaceutical waste, and the medicine must not be disposed of in household waste or wastewater.